Accepted Manuscript

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions

Adrian Selim, Andrew S. Moore

PII: S1525-1578(17)30485-3

DOI: 10.1016/j.jmoldx.2018.03.005


Reference: JMDI 689

To appear in: The Journal of Molecular Diagnostics

Accepted Date: 27 March 2018

Please cite this article as: Selim A, Moore AS, Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions, *The Journal of Molecular Diagnostics* (2018), doi: 10.1016/j.jmoldx.2018.03.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Molecular minimal residual disease monitoring in acute myeloid leukaemia: challenges and future directions

Adrian Selim* and Andrew S. Moore*†‡

From the University of Queensland Diamantina Institute,* Translational Research Institute, Brisbane; the Oncology Services Group,† Children's Health Queensland Hospital and Health Service, Brisbane; and the UQ Child Health Research Centre,‡ The University of Queensland, Brisbane, Australia

Correspondence: Andrew S. Moore

Children's Health Queensland Research Directorate

Level 7, Centre for Children's Health Research

62 Graham St, South Brisbane, Queensland, 4101, Australia

Email: andy.moore@health.qld.gov.au

Running Head: Molecular MRD in AML

Funding: A.S.M. is supported by the Children's Hospital Foundation, Queensland.

Disclosures: None declared.

Download English Version:

https://daneshyari.com/en/article/8733321

Download Persian Version:

https://daneshyari.com/article/8733321

Daneshyari.com